Skip to main content
Smart Investors Daily
OV

NASDAQ · OVID

Ovid Therapeutics Inc.

Healthcare · Biotechnology

$2.40

Down-$0.14 (-5.51%)

Updated Nov 17, 2026, 2:38 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
117.35M
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
$1.18 – $3.11
Volume
2.8M
Avg. volume
2.89M

Price performance · OVID

OVID price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

OVID closed at $2.40 after 21 trading sessions, up 10.60% for the selected period.

Last close
$2.40
Period change
+10.60%
Period low
$2.16
Period high
$2.85
Daily close
View OHLC price history
OVID OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$2.52$2.655$2.37$2.402.8M
Nov 13, 2026$2.50$2.555$2.33$2.542.9M
Nov 12, 2026$2.77$2.77$2.51$2.552.92M
Nov 11, 2026$2.80$2.86$2.66$2.781.82M
Nov 10, 2026$2.76$2.87$2.64$2.802.31M
Nov 9, 2026$2.89$3.09$2.83$2.856.22M
Nov 6, 2026$2.56$2.945$2.5585$2.853.9M
Nov 5, 2026$2.74$2.7499$2.485$2.582.02M
Nov 4, 2026$2.50$2.79$2.375$2.743.61M
Nov 3, 2026$2.39$2.495$2.38$2.401.38M
Nov 2, 2026$2.55$2.60$2.37$2.392.34M
Oct 30, 2026$2.51$2.70$2.44$2.543.15M
Oct 29, 2026$2.45$2.58$2.405$2.562.04M
Oct 28, 2026$2.26$2.495$2.205$2.452.06M
Oct 27, 2026$2.18$2.28$2.10$2.261.69M
Oct 26, 2026$2.19$2.22$2.1213$2.155844.07K
Oct 23, 2026$2.31$2.32$2.12$2.162.02M
Oct 22, 2026$2.45$2.50$2.34$2.371.18M
Oct 21, 2026$2.37$2.65$2.345$2.475.01M
Oct 20, 2026$2.19$2.46$2.175$2.363.67M
Oct 19, 2026$2.18$2.225$2.14$2.171.64M

Latest OVID news

The latest Smart Investors Daily articles mentioning OVID.

OVID research

Overview

Company profile and research snapshot.

Company profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.50
Implied upside
—
Analysts
—
OVID recent ratings
DateFirmRatingTarget
Oct 15, 2026Wolfe ResearchOutperform—
Oct 9, 2026Cantor FitzgeraldOverweight—
Oct 6, 2026GuggenheimBuy—
Oct 5, 2026GuggenheimBuy—
Sep 11, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results

OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiationAdvancement of a pediatric formulation of OV329 is on track and Compa

Benzinga · Nov 10, 2026

Ovid Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 41.18 percent increase over losses of $(0.17) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.